Literature DB >> 11420571

Paroxetine: a review.

M Bourin1, P Chue, Y Guillon.   

Abstract

Paroxetine is a potent and selective serotonin reuptake inhibitor (SSRI) with currently approved indications for the treatment of depression, obsessive-compulsive disorder, panic disorder and social phobia. It is also used in the treatment of generalized anxiety disorder, post traumatic stress disorder, premenstrual dysphoric disorder and chronic headache. Paroxetine, a phenylpiperidine derivative, is the most potent inhibitor of the reuptake of serotonin (5-hydroxytryptamine, 5-HT) of all the currently available antidepressants including the class of SSRIs. It is a very weak inhibitor of norepinephrine (NE) uptake but it is still more potent at this site than the other SSRIs. The selectivity of paroxetine, i.e., the ratio of inhibition of uptake of norepinephrine to serotonin (NE/5-HT) is amongst the highest of the SSRIs. Paroxetine has little affinity for catecholaminergic, dopaminergic or histaminergic systems and by comparison with tricyclic antidepressants (TCAs) has, therefore, a reduced propensity to cause central and autonomic side effects. Paroxetine exhibits some affinity for the muscarinic cholinergic receptor but much less than the TCAs. In addition, the adaptive changes of somatodendritic (5-HT(1A)) and terminal (5-HT(1B/1D)) autoreceptors observed with paroxetine are different to those observed with TCAs; it also inhibits nitric oxide synthase. It is both a substrate and an inhibitor of cytochrome isoenzyme P450 2D6. Paroxetine is well absorbed orally and undergoes extensive first pass metabolism that is partially saturable. Its metabolites are pharmacologically inactive in vivo. Steady state levels are achieved after 4-14 days and an elimination half-life of 21 h is consistent with once-daily dosing. There is wide inter-individual variation in the pharmacokinetics of paroxetine in adults as well as in the young and the elderly with higher plasma concentrations and slower elimination noted in the latter. Elimination is also reduced in severe renal and hepatic impairment. Serious adverse events are, however, extremely rare even in overdose. In summary, paroxetine is well tolerated and effective in the treatment of both depressive and anxiety disorders across the age range.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11420571      PMCID: PMC6741642          DOI: 10.1111/j.1527-3458.2001.tb00189.x

Source DB:  PubMed          Journal:  CNS Drug Rev        ISSN: 1080-563X


  101 in total

1.  Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers.

Authors:  R Schlösser; H Wetzel; H Dörr; W Rossbach; C Hiemke; O Benkert
Journal:  Psychoneuroendocrinology       Date:  2000-05       Impact factor: 4.905

2.  Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

Authors:  M F Poirier; P Boyer
Journal:  Br J Psychiatry       Date:  1999-07       Impact factor: 9.319

3.  Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.

Authors:  D Baldwin; J Bobes; D J Stein; I Scharwächter; M Faure
Journal:  Br J Psychiatry       Date:  1999-08       Impact factor: 9.319

4.  Effects of paroxetine on heart period variability in patients with panic disorder: a study of holter ECG records.

Authors:  V K Yeragani; V C Jampala; E Sobelewski; J Kay; G Igel
Journal:  Neuropsychobiology       Date:  1999-09       Impact factor: 2.328

5.  A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa.

Authors:  D J Stein; M Berk; C Els; R A Emsley; L Gittelson; D Wilson; R Oakes; B Hunter
Journal:  S Afr Med J       Date:  1999-04

6.  Paroxetine in human breast milk and nursing infants.

Authors:  Z N Stowe; L S Cohen; A Hostetter; J C Ritchie; M J Owens; C B Nemeroff
Journal:  Am J Psychiatry       Date:  2000-02       Impact factor: 18.112

Review 7.  Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.

Authors:  C Sánchez; J Hyttel
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

8.  Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat.

Authors:  J F Cryan; C McGrath; B E Leonard; T R Norman
Journal:  Pharmacol Biochem Behav       Date:  1999-06       Impact factor: 3.533

9.  Excretion of paroxetine into breast milk.

Authors:  R Ohman; S Hägg; L Carleborg; O Spigset
Journal:  J Clin Psychiatry       Date:  1999-08       Impact factor: 4.384

10.  Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms.

Authors:  J P Redrobe; M Bourin; M C Colombel; G B Baker
Journal:  J Psychopharmacol       Date:  1998       Impact factor: 4.153

View more
  35 in total

1.  Syndrome of inappropriate secretion of antidiuretic hormone associated with paroxetine.

Authors:  Takeshi Kubota; Akimasa Miyata
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

2.  No effects of enhanced central norepinephrine on finger-sequence learning and attention.

Authors:  Christian Plewnia; Julia Hoppe; Christian Gerloff
Journal:  Psychopharmacology (Berl)       Date:  2006-06-10       Impact factor: 4.530

3.  A Novel Bromine-Containing Paroxetine Analogue Provides Mechanistic Clues for Binding Ambiguity at the Central Primary Binding Site of the Serotonin Transporter.

Authors:  Rachel D Slack; Ara M Abramyan; Helen Tang; Sitaram Meena; Bruce A Davis; Alessandro Bonifazi; JoLynn B Giancola; Jeffrey R Deschamps; Sett Naing; Hideaki Yano; Satinder K Singh; Amy Hauck Newman; Lei Shi
Journal:  ACS Chem Neurosci       Date:  2019-08-22       Impact factor: 4.418

4.  FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications.

Authors:  N C Gassen; J Hartmann; A S Zannas; A Kretzschmar; J Zschocke; G Maccarrone; K Hafner; A Zellner; L K Kollmannsberger; K V Wagner; D Mehta; S Kloiber; C W Turck; S Lucae; G P Chrousos; F Holsboer; E B Binder; M Ising; M V Schmidt; T Rein
Journal:  Mol Psychiatry       Date:  2015-04-07       Impact factor: 15.992

5.  Computation-guided analysis of paroxetine binding to hSERT reveals functionally important structural elements and dynamics.

Authors:  Ara M Abramyan; Rachel D Slack; Sitaram Meena; Bruce A Davis; Amy Hauck Newman; Satinder K Singh; Lei Shi
Journal:  Neuropharmacology       Date:  2018-11-01       Impact factor: 5.250

6.  Initiation of illusions after combination of zolpidem and paroxetine in a young woman: a case report.

Authors:  Demetris Skourides; Lampros Samartzis
Journal:  Prim Care Companion CNS Disord       Date:  2012-07-19

7.  Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure.

Authors:  Feng Li; Mian Zhang; Dan Xu; Can Liu; Ze-Yu Zhong; Ling-Ling Jia; Meng-Yue Hu; Yang Yang; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-06       Impact factor: 6.150

8.  Rapid Construction of (-)-Paroxetine and (-)-Femoxetine via N-Heterocyclic Carbene Catalyzed Homoenolate Addition to Nitroalkenes.

Authors:  Nicholas A White; Kerem E Ozboya; Darrin M Flanigan; Tomislav Rovis
Journal:  Asian J Org Chem       Date:  2014-04       Impact factor: 3.319

9.  NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test.

Authors:  Mehdi Ghasemi; Laleh Montaser-Kouhsari; Hamed Shafaroodi; Behtash Ghazi Nezami; Farzad Ebrahimi; Ahmad Reza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2009-07-16       Impact factor: 4.530

10.  Paroxetine overdose.

Authors:  Arun K Gupta; Pankaj Verma; Samir K Praharaj; Dipayan Roy; Anuradha Singh
Journal:  Indian J Psychiatry       Date:  2005-07       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.